Analytical Validation of a Highly Quantitative, Sensitive, Accurate, and Reproducible Assay (HERmark^®) for the Measurement of HER2 Total Protein and HER2 Homodimers in FFPE Breast Cancer Tumor Specimens
Rivera, Amber, Cook, Jennifer W., Paquet, Agnes C., Defazio-Eli, Lisa, Tan, Yuping, Goodman, Laurie J., Larson, Jeffrey S., Frankson, Kristi, Bose, Jolly, Chen, Lili, Cheung, Judy, Shi, Yining, Irwin, Sarah, Kiss, Linda D. B., Huang, Weidong, Utter, Shannon, Sherwood, Thomas, Bates, Michael, Weidler, Jodi, Parry, Gordon, Winslow, John, Petropoulos, Christos J., Whitcomb, Jeannette M.
Published in Pathology Research International (28.06.2010)
Published in Pathology Research International (28.06.2010)
Get full text
Journal Article
Neratinib efficacy in a subgroup of patients with EGFR exon 18 - mutant non-small cell lung cancer (NSCLC) and central nervous system (CNS) involvement: Findings from the SUMMIT basket trial
Goldman, Jonathan Wade, Viteri Ramirez, Santiago, Mahipal, Amit, Suga, Jennifer Marie Marie, Eli, Lisa DeFazio, Lalani, Alshad S., Bryce, Richard, Xu, Feng, Shah, Naisargee, Kabbinavar, Fairooz, Boni, Valentina, Haley, Barbara B.
Published in Journal of clinical oncology (20.05.2021)
Published in Journal of clinical oncology (20.05.2021)
Get full text
Journal Article
Neratinib plus fulvestrant plus trastzuzumab (N+F+T) for hormone receptor-positive (HR+), HER2-negative, HER2 -mutant metastatic breast cancer (MBC): Outcomes and biomarker analysis from the SUMMIT trial
Jhaveri, Komal L., Goldman, Jonathan W., Hurvitz, Sara A., Guerrero-Zotano, Angel, Unni, Nisha, Brufsky, Adam, Park, Haeseong, Waisman, James Ross, Yang, Eddy Shih-Hsin, Spanggaard, Iben, Reid, Sonya A., Burkard, Mark E., Prat, Aleix, Loi, Sherene, Crown, John, Hanker, Ariella, Ma, Cynthia X., Bose, Ron, Eli, Lisa DeFazio, Wildiers, Hans
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
Targeting HER2 mutation–positive advanced biliary tract cancers with neratinib: Final results from the phase 2 SUMMIT basket trial
Harding, James J., Piha-Paul, Sarina Anne, Shah, Ronak H., Cleary, James M., Quinn, David I., Brana, Irene, Moreno, Victor, Borad, Mitesh J., Loi, Sherene, Spanggaard, Iben, Ford, James M., DiPrimeo, Daniel, Berger, Michael F., Eli, Lisa DeFazio, Meric-Bernstam, Funda, Solit, David B., Abou-Alfa, Ghassan K.
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action
DeFazio-Eli, Lisa, Strommen, Kristi, Dao-Pick, Trang, Parry, Gordon, Goodman, Laurie, Winslow, John
Published in Breast cancer research : BCR (15.04.2011)
Published in Breast cancer research : BCR (15.04.2011)
Get full text
Journal Article
Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110α Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers
GARRETT, Joan T, SUTTON, Cammie R, KURUPI, Richard, BIALUCHA, Carl Uli, ETTENBERG, Seth A, COLLINS, Scott D, QING SHENG, WALLWEBER, Jerry, DEFAZIO-ELI, Lisa, ARTEAGA, Carlos L
Published in Cancer research (Chicago, Ill.) (01.10.2013)
Published in Cancer research (Chicago, Ill.) (01.10.2013)
Get full text
Journal Article
Prolonged Response to Trastuzumab in a Patient With HER2-Nonamplified Breast Cancer With Elevated HER2 Dimerization Harboring an ERBB2 S310F Mutation
Chumsri, Saranya, Weidler, Jodi, Ali, Siraj, Balasubramanian, Sohail, Wallweber, Gerald, DeFazio-Eli, Lisa, Chenna, Ahmed, Huang, Weidong, DeRidder, Angela, Goicocheal, Lindsay, Perez, Edith A
Published in Journal of the National Comprehensive Cancer Network (01.09.2015)
Published in Journal of the National Comprehensive Cancer Network (01.09.2015)
Get more information
Journal Article
Abstract 5461: A HER3 antibody that blocks ligand-independent HER2-HER3 dimerization sensitizes to HER2 and PI3K inhibitors
Garrett, Joan T., Sutton, Cammie R., Bialucha, Carl Uli, Ettenberg, Seth A., Wallweber, Jerry, DeFazio-Eli, Lisa, Arteaga, Carlos L.
Published in Cancer research (Chicago, Ill.) (15.04.2013)
Published in Cancer research (Chicago, Ill.) (15.04.2013)
Get full text
Journal Article
Abstract 3029: Profiling HER3/ErbB3 activation in formalin-fixed, paraffin-embedded (FFPE) breast tumor samples that express high and low HER2/ErbB2 levels using proximity-based immunoassays
Wallweber, Jerry, Chenna, Ahmed, Ravanera, Roy, Huang, Weidong, Stathas, David, Marshall, Gayle, Womack, Chris, Pritchard, Alison, Thress, Ken, Barrett, Carl, Petropoulos, Christos, DeFazio Eli, Lisa, Winslow, John
Published in Cancer research (Chicago, Ill.) (15.04.2013)
Published in Cancer research (Chicago, Ill.) (15.04.2013)
Get full text
Journal Article
A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue
Shi, Yining, Huang, Weidong, Tan, Yuping, Jin, Xueguang, Dua, Rajiv, Penuel, Elicia, Mukherjee, Ali, Sperinde, Jeff, Pannu, Herjit, Chenna, Ahmed, DeFazio-Eli, Lisa, Pidaparthi, Sailaja, Badal, Youssouf, Wallweber, Gerald, Chen, Lili, Williams, Steve, Tahir, Hasan, Larson, Jeff, Goodman, Laurie, Whitcomb, Jeannette, Petropoulos, Christos, Winslow, John
Published in Diagnostic molecular pathology (01.03.2009)
Published in Diagnostic molecular pathology (01.03.2009)
Get more information
Journal Article